Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
0.9834
-0.0766 (-7.23%)
Mar 31, 2025, 1:24 PM EDT - Market open
Pyxis Oncology Stock Forecast
PYXS's stock price has decreased by -74.76% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Pyxis Oncology stock have an average target of 9.20, with a low estimate of 5.00 and a high estimate of 13. The average target predicts an increase of 835.53% from the current stock price of 0.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 2 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +713.50% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +408.44% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 → $5 | Strong Buy | Reiterates | $7 → $5 | +408.44% | Dec 20, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $10 → $8 | Buy | Reiterates | $10 → $8 | +713.50% | Dec 20, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $10 | Buy | Maintains | $7 → $10 | +916.88% | Nov 21, 2024 |
Financial Forecast
Revenue This Year
n/a
from 16.15M
Revenue Next Year
n/a
EPS This Year
-1.16
from -1.32
EPS Next Year
-1.07
from -1.16
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 26.3M | ||
| Avg | n/a | n/a | 8.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.97 | -0.76 | -1.04 | ||
| Avg | -1.16 | -1.07 | -1.24 | ||
| Low | -1.30 | -1.29 | -1.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.